RE:RE:RE:RE:SP Moving in Chunks Today! Spamme
your post proves that you are either very dense or a FUD-slinger plant.
Spectral/PMX is targeting a specific subset of Sepsis = Endotoxemic Septic Shock (ESS) Per multiple presentations this =140,000 patients annually. = $ 2 Billion USD* annual addressable market.
JK has explained multiple times why the Trial parameters are set up in such a way that it is difficult to find and get consent on the exact right group.
In the real world with FDA approval and PMX being the new SoC, landing a high portion of this subgroup will be much easier . And the addressable target may even expand depending on Bayesian analysis, EDEN studies, other real world studies, Euohas2, cautious doctors, etc etc
* with conservative pricing, US market only, old Sepsis stats, narrowish label, etc.
MM